Venture Certified
| 벤처투자유형 | 2024-01-17 ~ 2027-01-16 | 20240117010011 | 2024-01-17 |
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0.0B | 0.0B | 0.0B |
| Operating Profit | -3.1B | -3.2B | -0.2B |
| Net Profit | -2.6B | -3.2B | -0.2B |
| Total Assets | 5.7B | 4.1B | 0.9B |
| Total Liabilities | 4.6B | 0.5B | 0.1B |
| Total Equity | 1.1B | 3.6B | 0.8B |
Debt Ratio 424.9%: Exceeds 400%, financial soundness risk
Operating Loss: Op. profit -3B
3 Consecutive Years of Net Loss
Debt Ratio Surge (+411pp YoY)
- 0.0%
▼ 85.7%
▲ 3566.1%
▼ 333.5%
| Name | Position | Role |
|---|---|---|
| 홍성현 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "서울특별시 종로구",
"ceo_name": "홍성현",
"certificate": [
{
"cert_number": "20240117010011",
"changes": "",
"disclosure_date": "2024-01-17",
"first_cert_date": "2024-01-17",
"no": "1",
"type": "벤처투자유형",
"valid_period": "2024-01-17 ~ 2027-01-16"
}
],
"company_name": "(주)클리켐바이오",
"corp_no": "110111-*******",
"financials": {
"2022": {
"capital_stock": 100000000,
"cost_of_sales": 0,
"current_assets": 87969000,
"current_liabilities": 7591000,
"gross_profit": 0,
"net_income": -17622000,
"net_income_bs": -17622000,
"non_current_assets": 2000000,
"non_current_liabilities": 0,
"non_operating_expenses": 0,
"non_operating_income": 0,
"operating_profit": -17622000,
"revenue": 0,
"sga_expenses": 17622000,
"total_assets": 89969000,
"total_equity": 82378000,
"total_liabilities": 7591000
},
"2023": {
"capital_stock": 120870000,
"cost_of_sales": 0,
"current_assets": 356734000,
"current_liabilities": 50795000,
"gross_profit": 0,
"net_income": -318718000,
"net_income_bs": -318718000,
"non_current_assets": 57740000,
"non_current_liabilities": 0,
"non_operating_expenses": 1961000,
"non_operating_income": 253000,
"operating_profit": -317010000,
"revenue": 0,
"sga_expenses": 317010000,
"total_assets": 414474000,
"total_equity": 363679000,
"total_liabilities": 50795000
},
"2024": {
"capital_stock": 120870000,
"cost_of_sales": 0,
"current_assets": 528426000,
"current_liabilities": 459503000,
"gross_profit": 0,
"net_income": -255545000,
"net_income_bs": -255545000,
"non_current_assets": 39212000,
"non_current_liabilities": 0,
"non_operating_expenses": 123000,
"non_operating_income": 55217000,
"operating_profit": -310639000,
"revenue": 0,
"sga_expenses": 310639000,
"total_assets": 567638000,
"total_equity": 108135000,
"total_liabilities": 459503000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [
{
"amount": "300,012,000",
"changes": "300,012,000",
"date": "2023-07-20"
},
{
"amount": "100,004,000",
"changes": "100,004,000",
"date": "2023-07-20"
},
{
"amount": "100,004,000",
"changes": "100,004,000",
"date": "2023-07-20"
}
],
"main_products": "알부민 나노 플랫폼 항염증 및 항암 진단병합치료제 개발",
"phone": "010-2501-****",
"years": [
2024,
2023,
2022
]
}Data Quality: 8/10 | Primary Source: Venture System | Section Coverage: 6/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | Public Data | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Not Collected | Not Collected |
| Officers | Public Data | Collected |
| Employment | Not Collected | Not Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| G2B Procurement | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |
| Venture System Detail | 2026-02-25 | Collected |